Italy IVF (in-vitro fertilization) Market Overview, 2029

In the realm of in vitro fertilisation (IVF), Italy has become a major participant, exhibiting a landscape rich in knowledge, technology, and regulation. Italy, a country that emphasises family and has a strong healthcare system, has experienced a consistent increase in IVF treatments over time. The nation is home to a large number of specialised fertility clinics that are manned by highly qualified individuals such as reproductive endocrinologists, embryologists, and genetic counsellors and are furnished with cutting edge equipment. In addition, the regulatory environment in Italy guarantees that IVF procedures follow stringent ethical norms, giving patients peace of mind and comfort about the calibre and security of their reproductive process. Italy continues to push the limits of assisted reproductive technology, providing people and couples facing infertility with hope and answers via its groundbreaking work in reproductive medicine and cutting-edge methods like preimplantation genetic testing. Italy is a leader in the world of infertility, offering complete care and assistance to those starting a family with a combination of experience, technology, and ethical monitoring. The demand for fertility treatments is rising in Italy as a result of the country's ageing population and falling birth rates. As a result, the IVF market in Italy has grown quickly, resulting in a profusion of clinics and specialised services that meet the various demands of patients. Besides, preimplantation genetic testing and egg freezing, two recent developments in IVF technology, have strengthened the procedure's attractiveness as a workable option for infertile couples. According to the research report "Italy Infertility Treatment Market Overview, 2029," published by Bonafide Research, the Italy Infertility Treatment market is anticipated to grow at more than 7.2% CAGR from 2024 to 2029. Notable developments in the field of In Vitro Fertilisation (IVF) have occurred in Italy in recent years, which may be attributed to both scientific improvements and changing public perceptions about reproductive treatments. The growing use of pre-implantation genetic testing (PGT), which makes it possible to screen embryos for genetic abnormalities before implantation and increases the success rates of in vitro fertilisation (IVF) procedures while lowering the risk of genetic disorders in offspring, is one noteworthy development. Furthermore, customised fertility treatments are becoming more and more popular in Italy. Clinics there are providing customised methods—such as optimised ovarian stimulation regimens and embryo transfer techniques—based on the unique demands and features of each patient. Also, the advent of state-of-the-art technology like time-lapse imaging systems has made it possible to continuously monitor the growth of embryos, which has increased pregnancy rates and allowed for more accurate embryo selection. Fertility preservation services have expanded significantly in tandem with technology improvements to meet the needs of individuals who wish to maintain their fertility for potential future family planning attempts. These advancements change the face of the IVF industry in Italy by demonstrating the nation's dedication to enhancing reproductive care and offering creative solutions to those who are facing infertility.

IVF cycles and other assisted reproductive technologies are subject to strict regulations in France that put accessibility and safety first. Ovarian stimulation is used in a new, non-donor IVF round to harvest eggs from the intended mother. After fertilising these eggs in a lab environment with sperm, the resultant embryos are placed into the uterus. During ovarian stimulation, patients are often monitored with ultrasound and blood tests on a regular basis, necessitating many medical visits. Individual characteristics like age and reproductive health can have an impact on the success rates of new non-donor IVF cycles. Embryos produced in a prior fresh round are frozen and kept for later use in a frozen non-donor IVF cycle. In this cycle, hormone therapy is used to prepare the uterus for embryo transfer without the requirement for ovarian stimulation. As a result, fewer medical visits are required than with new cycles. Non-donor frozen IVF cycles provide for scheduling flexibility and can produce success rates that are similar to those of fresh rounds. Frozen embryos from a donor—either egg or sperm—are utilised to transfer embryos into the recipient's uterus during an IVF cycle. Since the main goal of this cycle is to prepare the recipient's uterus for embryo transfer, it usually entails less stringent monitoring and fewer medical visits than fresh cycles. Because they are more convenient to use than fresh donor cycles, frozen donor IVF cycles may have greater success rates because of superior embryo selection. Embryos created from a fresh donor IVF cycle are placed into the recipient's uterus after the donor's eggs are extracted and fertilised with sperm in a lab. This cycle necessitates regular monitoring of both the donor and recipient and needs synchronisation of their menstrual periods. Because of the intricate cooperation between the donor and recipient, there can be more medical visits than with other cycle types. Alternatively, frozen non-donor IVF cycles have become more and more common in France as of late. These cycles have similar success rates as new cycles and a lighter treatment load with fewer doctor visits, among other benefits. Furthermore, the French legislative framework—which places a strong emphasis on patient safety and ethical issues in assisted reproduction—aligns well with the capacity to preserve and use frozen embryos. Thus, a trend towards more effective and patient-friendly reproductive procedures has led to the rise in popularity of frozen non-donor IVF cycles among French patients and healthcare professionals. Conventional in vitro fertilisation, or IVF, is a popular assisted reproductive method in France. It is the process by which sperm fertilise eggs outside of the body in a lab. This process involves taking sperm and eggs out of the woman's ovaries, combining them in a petri dish, and then transferring the resultant embryos into the woman's uterus. Couples who are having trouble conceiving frequently choose for this operation for a variety of reasons, including clogged fallopian tubes, low sperm counts, or infertility that is not explained. To treat male infertility issues, another procedure used in France is IVF with ICSI (Intracytoplasmic Sperm Injection). ICSI is injecting a single sperm directly into an egg to promote fertilisation, as opposed to traditional IVF, which only mixes sperm and eggs. Couples with significant male infertility problems—such as low sperm count, poor motility, or aberrant sperm morphology—will find this approach very helpful. For these couples, IVF combined with ICSI has greatly increased the odds of conception and pregnancy. When a French couple is unable to conceive with their own eggs, they frequently explore IVF with donor eggs. This might be brought on by an older mother, low-quality eggs, or certain illnesses that interfere with the production of eggs. In this process, the male partner's sperm is inoculated into the eggs of a healthy donor by in vitro fertilisation (IVF), and the resultant embryos are then placed into the uterus of the recipient lady. Couples with infertility might find hope via donor egg IVF, which gives them the chance to get pregnant and give birth. Finally, more breakthroughs and variations in assisted reproductive technologies are offered in France to meet the unique demands and situations of individuals as well as couples. These might involve methods like embryo storage for later use, preimplantation genetic testing (PGT) to check embryos for genetic problems before to implantation, or surrogacy agreements for couples unable to carry a pregnancy to term. These alternatives give people and couples pursuing motherhood in France hope and possibilities, reflecting the ongoing innovation and growth in the field of reproductive medicine. Fertility clinics are essential in helping people and couples in France who are having trouble conceiving by offering reproductive health treatments. These clinics provide a variety of medical services, including egg freezing, artificial insemination, and in vitro fertilisation (IVF). They provide patients individualised care and support as they navigate the psychological and physical difficulties associated with reproductive therapy. Fertility clinics in France are regarded as reliable establishments by hopeful parents who are looking for help beginning or growing their family since they follow stringent rules guaranteeing the safety and ethical standards of treatments. In France, hospitals and surgical centres play a crucial role in the healthcare system by providing a comprehensive range of medical treatments, including specialised operations and procedures related to reproduction. For complicated reproductive treatments like laparoscopic surgery for endometriosis or tubal operations to address reproductive system defects, these centres provide state-of-the-art facilities and expertise. Modern equipment and highly qualified medical staff guarantee that patients in French hospitals and surgical centres receive thorough care and achieve the best possible results in their reproductive journeys. In France, cryobanks are essential for preserving reproductive organs and cells for later use. These facilities let people to retain their fertility for personal or medical reasons by gathering, processing, and storing gametes (eggs and sperm). Strict guidelines for the processing and preservation of reproductive resources are followed by cryobanks to guarantee their long-term safety and viability. Cryobanks are an invaluable resource for persons in France who are preparing for future family planning or who are undergoing fertility preservation before receiving medical treatments like radiation therapy or chemotherapy. Through scientific investigation and inventiveness, research institutions in France make a substantial contribution to the improvement of reproductive technology and medicine. These institutes carry out state-of-the-art research in fields including genetics, embryology, and reproductive endocrinology in an effort to enhance fertility therapies and results. In order to advance the area of reproductive health, researchers work in conjunction with fertility clinics and medical experts to convert scientific findings into clinical practice. Research institutions in France are essential to the future direction of fertility care and provide hope to people and couples struggling with infertility.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029 Aspects covered in this report • IVF market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

By cycle • Fresh Non-donor IVF Cycle • Frozen Non-donor IVF Cycle • Frozen donor IVF Cycle • Fresh donor IVF Cycle By Conventional IVF • Conventional IVF • IVF with ICSI (Instracytoplasmic Sperm Injection) • IVF With Donor Eggs • other By End user • Fertility Clinics • Hospital & Surgical Centers • Cryobanks • Research institute The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.